NLS Collaboration

Sobi is planning to include a new preclinical hemophilia project in an agreement with Biogen Idec. Accodring to an announcement, Sobi has elected to add the preclinical rFVIIIFc-XTEN-vWF fusion molecule to the company’s collaboration with Biogen Idec. The XTEN technology is proprietary to Amunix Operating, Inc.. Biogen Idec and Amunix signed a worldwide license agreement […]

Recipharm forms a new collaboration with Isofol Medical to manufacture Isofol’s drug candidate Modufolin. Furthermore, the life science sector investor Recipharm Venture Fund has announced that it has invested SEK 8 million in Isofol Medical. Isofol Medical AB is currently evaluating its drug candidate Modufolin in two clinical phase I/II studies. Modufolin is an endogenous […]

AstraZeneca has entered into a collaboration with gene sequencing company, Illumina, Inc., to develop its next generation sequencing (NGS) platform for companion diagnostic tests. In the first instance, AstraZeneca intends to apply Illumina’s technology to a novel companion diagnostic test in pivotal studies for one of its investigational oncology compounds. This is expected to be […]

AstraZeneca has entered a new collaboration with Dutch Qiagen and a partnership with Roche. The company has entered into a collaboration with Netherlands-based Qiagen to develop a non-invasive diagnostic test to identify non-small cell lung cancer (NSCLC) patients who are suitable for treatment with IRESSA, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that blocks […]

MedImmune has entered into a clinical trial collaboration with Advaxis, Inc., a US-based biotechnology company developing cancer immunotherapies. The two companies will collaborate on a Phase I/II immunotherapy study to evaluate the safety and efficacy of MedImmune’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Advaxis’ lead cancer immunotherapy vaccine, ADXS-HPV, as a treatment for patients with advanced, recurrent […]

Recipharm Karlskoga AB and Pharmanest AB form a collaboration for commercial manufacture and supply of SHACT. SHACT is a product based on a formulation of the anesthetic lidocaine and a proprietary application device developed to simplify topical application in the cervix and uterus. It is applied topically in the cervix and uterus with a device developed by Pharmanest. […]